Yükleniyor... / Loading...
This study investigates VERVE-101, a gene-editing therapy, in people with familial hypercholesterolemia and established cardiovascular disease. Patients aged 18-75 diagnosed with inherited high cholesterol (HeFH) and atherosclerotic cardiovascular disease could take part. The study was conducted in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Male and/or female participants 18 up to 75 years at time of signing of informed consent * Female participants not of child-bearing potential * Diagnosis of HeFH * Established ASCVD Exclusion Criteria: * Active or history of chronic liver disease * Current treatment with PCSK9 monoclonal antibody therapy * Current or past treatment with inclisiran * Clinically significant or abnormal laboratory values as defined by the protocol